[18F]FE-PE2I PET 测量帕金森病患者多巴胺转运体的可靠性
该研究纳入9例Hoehn-Yahr分期<3的帕金森病患者,在7-28天内进行两次[18F]FE-PE2I PET测量,评估多巴胺转运体结合潜能的重测信度。结果显示纹状体区域绝对变异性为5.3-7.6%,黑质为11%,ICC为0.74-0.97;纹状体功能亚区绝对变异性为6.0-9.6%,ICC为0.76-0.91。结论认为[18F]FE-PE2I PET在帕金森病患者中具有良好的重复性和可靠性,适合作为纵向监测多巴胺转运体下降的标志物。
要点
- 纹状体区域绝对变异性5.3-7.6%,黑质11%,ICC中位数0.91。
- 纹状体功能亚区绝对变异性6.0-9.6%,ICC中位数0.91。
- 基于当前样本量,可检测纹状体5-11%、黑质28%的多巴胺转运体变化(把握度0.8,p<0.0125)。
核心结论
- [18F]FE-PE2I PET在帕金森病患者中显示良好的重复性和可靠性。
- 黑质可靠性略低可能与多巴胺转运体密度较低和解剖体积较小有关。
- 把握度计算提示[18F]FE-PE2I PET适合作为帕金森病纵向多巴胺转运体下降的标志物。
研究设计与样本
- 纳入9例帕金森病患者(男/女6/3,平均年龄65.2±6.8岁,Hoehn-Yahr分期<3)。
- 每例患者在7-28天内接受两次[18F]FE-PE2I PET测量。
- 结局指标为以小脑为参考区、经小波辅助参数成像生成的非可置换结合潜能。
- 主要分析区域为尾状核、壳核、腹侧纹状体和黑质,并对纹状体功能亚区进行探索性分析。
- 比较受累较重侧与较轻侧,并基于当前样本量进行把握度计算。
主要发现
- [18F]FE-PE2I在纹状体区域的绝对变异性估计为5.3-7.6%,黑质为11%。
- 纹状体区域ICC为0.74-0.97(中位数0.91)。
- 纹状体功能亚区绝对变异性为6.0-9.6%,ICC为0.76-0.91(中位数0.91)。
- 受累较轻侧黑质的一致性高于受累较重侧。
- 基于当前样本量,纹状体5-11%和黑质28%的多巴胺转运体变化可在把握度0.8(p<0.0125)下被检测到。
关键数值与推荐
- 纹状体区域绝对变异性5.3-7.6%,黑质11%。
- 纹状体区域ICC 0.74-0.97(中位数0.91)。
- 纹状体功能亚区绝对变异性6.0-9.6%,ICC 0.76-0.91(中位数0.91)。
- 可检测纹状体5-11%、黑质28%的多巴胺转运体变化,把握度0.8,p<0.0125。
临床怎么用
- [18F]FE-PE2I PET可用于帕金森病患者多巴胺转运体测量的重复性评估。
- 纹状体区域测量可靠性较好,适合纵向监测多巴胺转运体变化。
- 黑质测量变异性较高,解读结果时需谨慎。
局限性
- 样本量较小(9例帕金森病患者)。
- 仅纳入Hoehn-Yahr分期<3的患者。
- 黑质可靠性略低可能受多巴胺转运体密度和解剖体积影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Reliable quantification of dopamine transporter (DAT), a biomarker for Parkinson's disease (PD), is essential for diagnostic purposes as well as for evaluation of potential disease-modifying treatment. Due to degeneration of dopaminergic neurons and thus lower expected radioligand binding to DAT, higher measurement variability in PD patients might be expected than earlier reproducibility results in healthy controls. Therefore, we aimed to examine the test-retest properties of [18F]FE-PE2I-PET in PD patients. METHODS: Nine patients with PD (Hoehn and Yahr stage < 3) were included (men/women 6/3; mean age 65.2 ± 6.8 years). Each patient underwent two [18F]FE-PE2I-PET measurements within 7-28 days. The outcome measure was non-displaceable binding potential generated using wavelet-aided parametric imaging with cerebellum as reference region. We assessed test-retest performance using estimates of reliability and repeatability. Regions for primary analysis were caudate, putamen, ventral striatum, and substantia nigra. Exploratory analysis was performed for functional subdivisions of the striatum. We also compared the more vs. less affected side. RESULTS: [18F]FE-PE2I showed absolute variability estimates of 5.3-7.6% in striatal regions and 11% in substantia nigra and ICCs of 0.74-0.97 (median 0.91). The absolute variability for functional striatal subdivisions was 6.0-9.6% and ICCs of 0.76-0.91 (median 0.91). The less affected substantia nigra exhibited greater consistency than the more affected side. According to power calculations based on the current sample size, DAT changes of 5-11% in the striatum and 28% in the substantia nigra can be detected with a power of 0.8 (p < 0.0125). CONCLUSION: DAT-PET measurements with [18F]FE-PE2I in PD patients showed good repeatability and reliability. The slightly lower reliability in the substantia nigra in patients may be explained by lower DAT density and smaller anatomical size. Power calculations suggest that [18F]FE-PE2I PET is a suitable marker for longitudinal DAT decline in PD. TRIAL REGISTRATION: EudraCT 2017-003327-29.
引用
- Kerstens VS, Fazio P, Sundgren M, et al. Reliability of dopamine transporter PET measurements with [18F]FE-PE2I in patients with Parkinson's disease. EJNMMI Res. 2020. PMID: 32797307. doi:10.1186/s13550-020-00676-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。